Darveau A, Chevrier M C, Néron S, Delage R, Lemieux R
Canadian Red Cross, Blood Services, Quebec city Centre, P.Q.
J Immunol Methods. 1993 Feb 26;159(1-2):139-43. doi: 10.1016/0022-1759(93)90151-v.
The use of peripheral B lymphocytes in the successful preparation of human monoclonal antibodies by hybridoma technology is highly dependent on lymphocyte activation procedures. We studied the ability of peripheral human B lymphocytes cultured in vitro and activated through their CD40 antigen (CD40 system) (Banchereau et al., 1991) to form antibody-secreting heterohybridomas after fusion with murine X63Ag8.653 myeloma cells. The frequency of antibody-secreting heterohybridomas formation was greatly increased (15 times) by culture of B cells in the CD40 system. The CD40 system offers many advantages over other procedures of B lymphocyte activation representing a significant technological advance in the preparation of human monoclonal antibodies by standard hybridoma technology.
通过杂交瘤技术成功制备人单克隆抗体时，外周血B淋巴细胞的使用高度依赖于淋巴细胞激活程序。我们研究了体外培养并通过其CD40抗原激活（CD40系统）（班切罗等人，1991年）的外周血人B淋巴细胞与鼠X63Ag8.653骨髓瘤细胞融合后形成分泌抗体的异种杂交瘤的能力。在CD40系统中培养B细胞，分泌抗体的异种杂交瘤形成频率大幅提高（15倍）。与其他B淋巴细胞激活程序相比，CD40系统具有许多优势，代表了标准杂交瘤技术在制备人单克隆抗体方面的一项重大技术进步。
